Core Viewpoint - The company expects a net profit attributable to shareholders of between -33 million to -26 million yuan for 2025, an improvement from -93.95 million yuan in the same period last year [1] Financial Performance - The anticipated performance change is primarily due to the recognition of investment income from increased equity in Boling Brain Machine and the recognition of non-operating income from the return of executed funds at Jianhua Hospital [1] - There is an increase in income tax expenses due to a reduction in the recognition of deferred tax assets at Kanghua Hospital and Jianhua Hospital, attributed to adjustments in medical insurance policies [1]

（记者 王晓波） 每经AI快讯，创新医疗1月29日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润为-2600万 元至-3300万元，基本每股收益-0.06元至-0.07元。上年同期净利润为-9395.4万元。 每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

南财智讯1月29日电，创新医疗发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-3300万元—-2600万元，同比预增64.88%—72.33%；预计2025年全年归属于上市公司股东的扣除非经 常性损益的净利润为-7500万元—-6800万元，同比预减14.14%—25.89%。业绩变动原因说明：1、本报 告期归属于上市公司股东的净利润出现同比上升，主要系：公司增持博灵脑机股权并将该公司纳入合并 报表范围，根据《企业会计准则第33号——合并财务报表》第四十八条的规定，确认了相应的投资收 益；李晔案件再审改判后，建华医院收到了法院返还的被执行款项，并由此确认了营业外收入。2、本 报告期扣除非经常性损益后的净利润出现同比下降，主要系：在医保政策以及医保支付标准持续调整的 行业背景下，康华医院、建华医院对短期盈利预期的不确定性进行了审慎评估，本报告期确认的递延所 得税资产同比减少，导致所得税费用出现同比上升。 ...

创新医疗公告，预计2025年度净利润为负值，归属于上市公司股东的净利润预计在-3300万元至-2600万 元之间，上年同期为-9395.4万元，比上年同期增长64.88%～72.33%。扣除非经常性损益后的净利润预 计在-7500万元至-6800万元之间，上年同期为-5957.41万元，比上年同期下降14.14%～25.89%。营业收 入预计在7.8亿元至8亿元之间，上年同期为8.16亿元。 ...

证券代码：002173 证券简称：创新医疗 公告编号：2026-005 创新医疗管理股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、预计的本期业绩情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值。 单位：万元 | 项 目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | | -3,300 | ～ | -2,600 | -9,395.40 | | | 比上年同期增长 | 64.88% | ～ | 72.33% | | | 扣除非经常性损益后的净利润 | | -7,500 | ～ | -6,800 | -5,957.41 | | | 比上年同期下降 | 14.14% | ～ | 25.89% | | | 基本每股收益（元/股） | | -0.07 | ～ | -0.06 | -0.21 | | 营业收入 | | 78,000 | ～ | 80, ...

全球脑机接口玩家奋楫争先，产业化落地谱写投资蓝图 20260128 摘要 创新药领域，减肥、小核酸及 2L 疗法值得关注。减肥和 IO 赛道市场规 模达千亿美元级别，具弹性机会。小核酸赛道也因高景气度备受关注。 全年维度来看，医药板块值得重点关注。 脑机接口商业化处于起步阶段，是 2026 年投资主线。植入式临床进展 迅速，心伟医疗、爱鹏医疗和乐普医疗安全性具优势。非侵入式方面， 翔宇、迈兰德、创新医疗和诚益通等公司靠前。 政策支持对脑机接口行业发展起到重要引领作用，2025 年推出发展目 标与产业规划蓝图，确立收费项目立项，提高公立医院购买积极性，为 未来纳入医保铺平道路。 脑机接口产业链核心技术壁垒集中于中上游，包括硬件（电极、芯片）、 手术机器人及算法处理等。国产替代进程加速，美好医疗率先卡位上游 并开始代工侵入型电极。 Neuralink 需定制 ASIC 芯片，因通用芯片无法在处理上千通道信号的 同时控制功耗。其关键部分是模拟前端，需实现微弱神经信号的放大、 滤波和数字化。 Q&A 目前医药板块的投资机会主要集中在哪些方向？ 当前医药板块的投资机会主要集中在创新药及其相关产业链上。尤其是一些龙 头企 ...

Core Insights - The National Medical Products Administration of China has approved two industry standards for medical devices utilizing brain-computer interface (BCI) technology, indicating a push for high-quality development in this sector [1] - Analysts believe that the BCI field is entering a critical window for expansion from research validation to clinical and consumer applications, driven by recent innovative policies in medical devices [1] Industry Overview - Neuralink, founded by Elon Musk, is a leading player in the global BCI field, planning to scale up production of BCI devices and explore automated surgical solutions [3] - The global BCI market is projected to reach approximately $2.6 billion in 2024, with an annual growth rate of 11.5%, and is expected to expand to $3.3 billion by 2026 [3] - McKinsey forecasts that the BCI market in the medical sector could reach around $40 billion by 2030 and further grow to about $145 billion by 2040, with central nervous system disease treatment as a primary application area [3] Domestic Development - China's top-level policy design is providing crucial support for the development of BCI technology, with a goal to achieve breakthroughs in key technologies and establish a standard system by 2027 [4] - The number of companies in China's BCI sector has exceeded 200, with a projected industry scale of tens of billions of RMB by 2026 and an estimated 10-14 billion RMB by 2030 [4] - Rumors suggest that Qiangnao Technology is preparing for an IPO in Hong Kong, potentially becoming the first company among the "Hangzhou Six Little Dragons" to enter the capital market [4] Company Activities - In the A-share market, there are currently 50 listed companies in the BCI sector [5] - Botao Biological has invested in Haoshi Tianhui Technology, focusing on non-invasive BCI and mental health applications, aiming to accelerate clinical transformation and industrialization of innovative technologies [5] - Tianqi Co., Ltd. is entering the core BCI sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, which is crucial for domestic BCI hardware localization [6] - Innovation Medical is positioning itself in the BCI industry through its subsidiary Boling Brain Machine, which has commercialized BCI rehabilitation products [6]

活动现场，无锡市市场监督管理局与香港标准及检定中心（STC）签署合作备忘录。STC是香港最具权 威性的检测认证服务机构之一，由无锡籍著名旅港爱国实业家唐翔千、丁午寿于1963年联合创立，现由 香港无锡商会荣誉会长唐庆年担任董事会主席，与无锡有着极为深厚的乡情纽带。 1月27日，"聚贤惠锡 双湾融合"2026香港各界人士无锡行持续进行中。当晚，举行了签约活动，涉及检 验检测认证、文化旅游等领域的一批优质合作项目签约落地，将进一步助推锡港两地合作。 现场，无锡海外联谊会名誉顾问、南联实业有限公司常务董事唐明千，无锡海外联谊会副会长、无锡旅 港同乡会会长荣康信，香港江苏社团总会常务副会长、香港无锡商会常务副会长黄华，香港无锡商会副 会长兼科创委员会会长、粤港澳无锡妇女总会执行会长王静娴，香港标准及检定中心董事会副主席、粤 港澳惠山同乡联谊会会长丁炜章等来锡香港嘉宾出席签约活动。 锡港情谊，血脉相融。近年来，无锡积极主动融入粤港澳大湾区建设，持续推进锡港两地在产业、科 创、人才、文化、旅游等多领域的协同合作，在此过程中，一大批关心家乡发展的无锡籍贤达为促进锡 港合作献智出力。 签约后，STC将与无锡市在检验检测认证领 ...

Core Insights - Nanjing Gulou Hospital is enhancing its medical capabilities through systematic planning and continuous investment, boasting 15 national key disciplines and clinical specialties, which significantly improve its overall diagnostic and treatment services [1][2] Group 1: Clinical Achievements - The orthopedic department, led by Professor Jiang Qing, has performed nearly 6,000 surgeries annually, maintaining the highest joint surgery volume in Jiangsu, and has developed a comprehensive prevention model that reduced postoperative thrombosis rates from 74% to 4% [2] - The neurology department, under Professor Xu Yun, is recognized as an international advanced stroke center and has developed an electronic screening platform that covers 52 community health service centers and 231 hospitals, enabling early detection of high-risk patients for Alzheimer's disease [3] - The reproductive medicine center has achieved a success rate of approximately 60% for in vitro fertilization, significantly higher than the national average, and is exploring cutting-edge stem cell technologies to assist previously hopeless infertility cases [3] Group 2: Research and Innovation - The hospital has a strong research foundation with 110 national-level talents and over 500 provincial-level talents, contributing to its high ranking in natural index and numerous prestigious awards [7] - Professor Zhu Dalong's team has developed a novel dual-target glucose-lowering drug, which is the first of its kind globally, addressing the weight gain issue associated with traditional diabetes medications [6] - The hospital has established a concept verification center and a clinical research institute, facilitating the transformation of research outcomes into clinical applications, with 59 successful transformations amounting to 226 million yuan [10] Group 3: Technological Advancements - The hospital is leveraging artificial intelligence in various applications, including a system that generates virtual X-rays from smartphone images for scoliosis screening, which has been patented and is set for community rollout [8] - A new olfactory detection device developed for early identification of cognitive impairments in diabetes patients has reduced screening time to 15 minutes and has already generated 20 million yuan in revenue [9] - The hospital's AI initiatives have improved diagnostic accuracy for pancreatic cancer and significantly reduced report writing time for medical imaging [11] Group 4: Strategic Goals - Nanjing Gulou Hospital aims to establish itself as a leading medical and research center, focusing on high-quality healthcare services and innovative medical solutions, with plans to apply for national medical center status and develop multiple top-tier disciplines [12]

Group 1 - The core theme of the conference was "innovation-driven," highlighted by the success story of the first small molecule targeted anti-cancer drug, Camrelizumab, developed by Betta Pharmaceuticals, which took nearly a decade from initiation in 2002 to market launch in 2011 [1] - The biopharmaceutical industry is experiencing unprecedented innovation opportunities due to the continuous change in disease patterns, which current treatment methods cannot fully address [2] - The integration of big data and artificial intelligence (AI) is revolutionizing new drug development, reducing the average research and development cycle and costs by approximately 50% [2] Group 2 - In the past year, China approved 76 innovative drugs and medical devices, with a total transaction value of over $130 billion for innovative drug licensing, marking a historical high and establishing China as a global source of pharmaceutical innovation [3] - The biopharmaceutical industry in Hangzhou is characterized by a collaborative ecosystem, with various stakeholders providing support to overcome challenges in drug development, particularly in preclinical research and clinical translation [4] - The Hangzhou Capital Group is actively supporting enterprises with core technologies and development potential, providing stable financial resources to facilitate innovation throughout the entire lifecycle of companies [4] Group 3 - Local institutions, including the Hangzhou Biobank and Tigermed, are committed to enhancing collaboration in resource sharing, professional services, and research platform construction to strengthen the innovation foundation of Hangzhou's biopharmaceutical industry [5]